This is the authors' abstract. We don't add key points for this paper.
The N-mAb case study was produced by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to support teaching and learning for both industry and to accelerate adoption of advanced manufacturing process technologies such as integrated continuous bioprocesses (ICB) for mAbs. Similar to the A-mAb case study, N-mAb presents the evolution of an integrated control strategy, from early clinical through process validation and commercial manufacturing with a focus on elements that are unique to integrated continuous bioprocesses. This publication presents a summary of the process design and characterization chapters to allow a greater focus on the unique elements relevant to that phase of development.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Brower et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: